Risk of heart failure hospitalization among users of dipeptidyl peptidase-4 inhibitors compared to glucagon-like peptide-1 receptor agonists

Cardiovascular Diabetology
Ghadeer K DawwasHaesuk Park

Abstract

Incretin-based therapies including dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon like peptide-1 (GLP-1) receptor agonists are novel medications for type 2 diabetes management. Several studies have found cardioprotective effects of incretin-based therapies; however, it remains unclear whether there is any difference in heart failure (HF) risk between the two incretin-based therapies (DPP-4 inhibitors and GLP-1 receptor agonists). We aimed to assess the risk of hospitalization due to HF with the use of DPP-4 inhibitors compared to GLP-1 receptor agonists. Using Truven Health Marketscan data, we conducted a retrospective cohort study of patients with type 2 diabetes, who were newly initiated on DPP-4 inhibitors or GLP-1 agonists. Follow-up continued from drug initiation until the first occurrence of: HF hospitalization (primary outcome), discontinuation of therapy (i.e. no fill for 7 days), switch to the comparator, end of enrollment, or end of study (December 2013). Cox proportional hazards models with propensity-score-matching were used to compare the risk of HF hospitalization between DPP-4 inhibitors and GLP-1 agonists. A total of 321,606 propensity score-matched patients were included in the analysis (n = 160,803 for...Continue Reading

References

Jan 25, 2012·Pharmacoepidemiology and Drug Safety·Jane S SaczynskiJerry H Gurwitz
Feb 11, 2012·Endocrine Reviews·John R Ussher, Daniel J Drucker
Aug 8, 2012·The Journal of Clinical Endocrinology and Metabolism·Adrian Vella
Sep 3, 2013·The New England Journal of Medicine·Benjamin M SciricaUNKNOWN SAVOR-TIMI 53 Steering Committee and Investigators
Aug 2, 2014·Therapeutic Advances in Drug Safety·Thomas KaragiannisApostolos Tsapas
Jun 9, 2015·The New England Journal of Medicine·Jennifer B GreenUNKNOWN TECOS Study Group
May 22, 2016·Diabetes Care·Kristian B Filion, Samy Suissa
Jul 16, 2016·European Heart Journal. Cardiovascular Pharmacotherapy·Faiez ZannadGonzalo Calvo
Apr 23, 2017·Diabetes & Metabolism·André J Scheen
Nov 9, 2017·Nutrition, Metabolism, and Cardiovascular Diseases : NMCD·P GargiuloP Perrone-Filardi
Dec 10, 2017·Diabetes Care·UNKNOWN American Diabetes Association

❮ Previous
Next ❯

Citations

Aug 30, 2019·Cardiovascular Diabetology·Yue FeiBernard Man Yung Cheung
Jul 8, 2020·Cardiovascular Diabetology·Bo Liang, Ning Gu

❮ Previous
Next ❯

Software Mentioned

SAS

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.